menu
    • menu
    [{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bellicum Enters Asset Purchase Agreement with MD Anderson","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bellicum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MD Anderson Research Freeze Stops Production of Bellicum Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Receives FDA IND Clearance to Initiate a Phase 1\/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T\u00ae for HER2+ Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-603","moa":"MyD88\/CD40","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bellicum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Announces Interim BPX-601 Data and Corporate Restructuring","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1\/2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Enrolls First Patient in Phase 1\/2 Clinical Trial for BPX-603","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-603","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.0 million","newsHeadline":"Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe\u00ae Safety Switch","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Cellular Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Canter","highestDevelopmentStatusID":"1","companyTruncated":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Canter"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"MTS Securities","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bellicum Announces Positive Interim Data from Phase 1\/2 GoCAR-T\u00ae Studies, Secures $35 Million Private Placement Equity Financing Priced at Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Private Placement","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ MTS Securities","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ MTS Securities"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Discontinues Phase 1\/2 Trials and Initiates Evaluation of Strategic Alternatives","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Bellicum Pharmaceuticals

    Menu

    Bellicum Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BPX-601,Rimiducid

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives

                            Details : BPX-601 incorporates high-performance GoCAR-T™ technology designed to target and treat solid tumors expressing prostate stem cell antigen (PSCA). It is being discontinued following the company’s assessment of BPX-601 risk/benefit profile in combinati...

                            Brand Name : BPX-601

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 14, 2023

                            Lead Product(s) : BPX-601,Rimiducid

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BPX-601,Rimiducid

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitour...

                            Details : BPX-601 is our first clinical candidate incorporating our high-performance GoCAR-Tâ„¢ technology designed to target and treat solid tumors expressing prostate stem cell antigen (PSCA).

                            Brand Name : BPX-601

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 19, 2023

                            Lead Product(s) : BPX-601,Rimiducid

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BPX-601,Rimiducid

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : MTS Securities

                            Deal Size : $35.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placeme...

                            Details : Proceeds from the financing will be used to support ongoing clinical development of BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.

                            Brand Name : BPX-601

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 06, 2021

                            Lead Product(s) : BPX-601,Rimiducid

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : MTS Securities

                            Deal Size : $35.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cellular Therapy,Inducible Caspase-9,Rimiducid

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch

                            Details : Under this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs. The CaspaCIDe switch consists of the CID-binding domain coupled to the signaling domain of caspase-9, an enzyme that is part of the ap...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $5.0 million

                            September 01, 2021

                            Lead Product(s) : Cellular Therapy,Inducible Caspase-9,Rimiducid

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BPX-603,Rimiducid

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603

                            Details : BPX-603 is Bellicum’s first dual switch GoCAR-T product candidate that incorporates the company’s iMC activation and CaspaCIDe safety switch technologies. Phase 1/2 trial will investigate the safety, tolerability, and clinical activity of BPX-603, ad...

                            Brand Name : BPX-603

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 10, 2020

                            Lead Product(s) : BPX-603,Rimiducid

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BPX-601,Rimiducid

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial

                            Details : The FDA is taking this action due to the death of a pancreatic cancer patient in the trial reported to the agency by the company. The clinical investigator and Bellicum classified the patient death as unrelated to BPX-601 and rimiducid.

                            Brand Name : BPX-601

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 07, 2020

                            Lead Product(s) : BPX-601,Rimiducid

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BPX-601,Rimiducid

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bellicum Announces Interim BPX-601 Data and Corporate Restructuring

                            Details : Findings from the first four patients treated with BPX-601 followed by repeat rimiducid dosing showed evidence of rimiducid-mediated CAR-T cell activation. Clinically meaningful efficacy as measured by RECIST criteria was not observed.

                            Brand Name : BPX-601

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 29, 2020

                            Lead Product(s) : BPX-601,Rimiducid

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BPX-603

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-TÂ...

                            Details : BPX-603 is the company’s first dual-switch GoCAR-T® product candidate, which incorporates both the company’s iMC activation and CaspaCIDe® safety switch technologies.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 15, 2020

                            Lead Product(s) : BPX-603

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BPX-601,Rimiducid

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MD Anderson Research Freeze Stops Production of Bellicum Drugs

                            Details : Bellicum is currently involved in 12 active studies, including a phase 1/2 trial of BPX-601 CAR-T cells in advanced solid tumors that express high levels of PSCA.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 17, 2020

                            Lead Product(s) : BPX-601,Rimiducid

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Bellicum Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BPX-601,Rimiducid

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium

                            Details : A cohort treated with BPX-601 and a single dose of rimiducid showed immunomodulation in both the periphery and tumor microenvironment.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 24, 2020

                            Lead Product(s) : BPX-601,Rimiducid

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth